mRNA Vaccines Pipeline Insights: Key Developments to Watch in 2025

Latest Pipeline Insights on mRNA Vaccines Market 2025
mRNA vaccines use synthetic messenger RNA to instruct cells to produce a protein that triggers an immune response. They gained prominence during the COVID-19 pandemic due to their rapid development and high efficacy. Unlike traditional vaccines, they do not contain live virus components. mRNA vaccines are also being explored for treating other infectious diseases and cancers. They represent a revolutionary shift in vaccine technology.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://www.datamintelligence.com/download-sample/mrna-vaccines-market---pipeline-insights?rk

List of the Key Players in the mRNA Vaccines Market:

☛ Moderna, Inc.

mRNA-1283: mRNA-1283 is Moderna's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2.

☛ BioNTech SE

BNT111: BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. BNT111 induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens, which are expressed in more than 90% of cutaneous melanomas. BNT111 is one of four clinical-stage FixVac product candidates within BioNTech's development pipeline.

⇥ Sanofi

⇥ GSK plc

⇥ AstraZeneca

⇥ Merck & Co., Inc.

⇥ F. Hoffmann-La Roche Ltd

⇥ RinuaGene

Industry Development:

✔ In January 2025, Moderna, Inc. revealed continued support from the U.S. Department of Health and Human Services (HHS) to fast-track the development of mRNA-based pandemic influenza vaccines. This collaboration is facilitated through the Rapid Response Partnership Vehicle (RRPV) Consortium, with funding from the Biomedical Advanced Research and Development Authority (BARDA), a division of the HHS Administration for Strategic Preparedness and Response (ASPR).

Merger and Acquisitions
✦ In June 2024, Moderna, Inc. and Merck unveiled the first results from the planned analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study. This clinical trial evaluates mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy. The study focuses on patients with resected high-risk melanoma (stage III/IV) who have undergone complete resection, involving a cohort of 157 participants.

Assessing the Effects of U.S. Tariffs on the Market

The U.S. tariff war is reshaping how businesses analyze trends and make strategic decisions. As tariffs drive up costs and disrupt supply chains, companies are increasingly focused on understanding consumer behavior, identifying new sourcing opportunities, and adjusting their operations to remain competitive. The ongoing uncertainty has created a stronger demand for timely insights and data-driven strategies to navigate shifting trade dynamics and economic pressures.

Research Process:

Both primary and secondary data sources have been used in the global mRNA Vaccines Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/mrna-vaccines-market---pipeline-insights?rk

Regulatory Designations
» In January 2025, Moderna, Inc. announced continued support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. This collaboration is facilitated through the Rapid Response Partnership Vehicle (RRPV) Consortium, with funding from the Biomedical Advanced Research and Development Authority (BARDA), a part of the HHS Administration for Strategic Preparedness and Response (ASPR).

» In November 2024, Arcturus Therapeutics Holdings Inc. revealed that the U.S. Food and Drug Administration (FDA) granted a "Study Can Proceed" notification for its Investigational New Drug (IND) application. The application pertains to ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate designed for active immunization to prevent pandemic influenza caused by the H5N1 virus.

Regional Analysis for mRNA Vaccines Market:

The regional analysis of the mRNA Vaccines Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/mrna-vaccines-market---pipeline-insights?rk

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the mRNA Vaccines market?

➠ Who are the leading manufacturers in the global mRNA Vaccines industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global mRNA Vaccines industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the mRNA Vaccines market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports: https://www.datamintelligence.com/research-report/mrna-vaccines-market---pipeline-insights?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.